Reference is made to the stock exchange announcement published on 30 November
2023 by Exact Therapeutics AS ("Exact-Tx" or the "Company") regarding a
completed private placement (the "Private Placement") of new shares in the
Company. 

The issuance of 2,083,333 new shares has now been registered with the Norwegian
Register of Business Enterprises (the "NRBE") (Nw: Foretaksregisteret).
Following registration of the share capital increase, the Company's  share
capital is NOK 128,322.208  divided into 32,080,552 shares, each with a par
value of NOK 0.004. 

This information is subject to the disclosure requirements pursuant to Euronext
Growth Oslo Rule Book - Part II, section 3.11.5 (3). 

For more information, please contact: 
CEO Per Walday, per.walday@exact-tx.com
CFO John M. Edminson, john.edminson@exact-tx.com

About EXACT-Tx: 
EXACT-Tx is a Norwegian clinical-stage precision medicine company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy) and brain diseases.
www.exact-tx.com